Urb. Colinas de Guataparo Nro. 201-130, Valencia Edo. Carabobo
ZP: 2001 Contacto: 0424-451.06.32
| NAME OF RESEARCH | RESULT | REFERENCE INTERVAL | UNIT MEASUREMENTS |
|---|---|---|---|
| Total bacterial mass (TBM) | |||
| Total bacterial mass (TBM) | 6.5* | > 6.0 | Lg (GE/g) |
| Normal microbiota | |||
| diversity, number of taxa | 10 | ≥ 10 | PCS |
| proportion | 97.8 | ≥ 80 | % |
| Bifidobacterium spp. | |||
| metabolically active "child" species, diversity | Not assessed at this age | ||
| metabolically active "child" species, proportion** | Not assessed at this age | ||
| metabolically active species, proportion | > 10 | ≥ 10 | % |
| total amount | 4.6* ↘ | > 6.0 | Lg (GE/g) |
| Lactobacillaceae, quantity | - | > 0.0 | Lg (GE/g) |
| Bacteroidetes, presence | detected | detected | |
| Firmicutes/Bacteroidetes ratio | 1.9 | ≥ 1.5 | |
| Yeast fungi, quantity | 5.8* | < 6.5 | Lg (GE/g) |
| Opportunistic pathogens, proportion | 2.2 | < 20 | % |
| Markers of pathogenicity and resistance, presence | |||
| Candida albicans | not detected | not detected | |
| Clostridioides difficile | - | 0.0 | Lg (GE/g) |
| mecA | not detected | not detected | |
| pathogenic agents Enterobacterales | not detected | not detected | |
| Staphylococcus aureus | - | < 4.5 | Lg (GE/g) |
| Streptococcus agalactiae with srr2 | Not assessed at this age | ||
| tcdA, tcdB | not detected | not detected |
Urb. Colinas de Guataparo Nro. 201-130, Valencia Edo. Carabobo
ZP: 2001 Contacto: 0424-451.06.32
Consideraciones:
Escriba aqui las consideraciones clinicas del paciente.
Recomendaciones nutricionales generales:
Objetivos:
Probioticos recomendados por fase:
Consideraciones: DISBIOSIS METABÓLICA LEVE NO INFLAMATORIA
1-Biomasa total dentro de los parámetros para la edad.
2-Excelente capacidad antinflamatoria colónica.
3-Perfil funcional proteolítico con elevación de metabolitos clave y ácidos biliares secundarios, aún sin daño mucoso.
4-Diversidad bacteriana adecuada a la edad.
5-Déficit de simbiontes protectores.
6-Barrera intestinal protegida.
7-Excelente potencial colónico funcional.
8-Sin riesgo de permeabilidad intestinal.
9-Leve sobre-crecimiento micótico,
Recomendaciones nutricionales generales:
Con el objetivo de modular la microbiota, se recomienda implementar una alimentación antiinflamatoria, basada en vegetales cocidos, frutas bajas en FODMAPs, y proteínas de alto valor biológico, preferiblemente pescado. Debe evitar durante 8 semanas el consumo de carne roja, huevos, embutidos, trigo, vinagre balsámico, refrescos, azucares refinados, lácteos sin no son fermentados, antibióticos sin prescripción medica, edulcorantes y alimentos ultraprocesados e industrializados.
Considerando la edad del paciente, aumentar progresivamente el consumo de:
• Frutos rojos, kombucha sin azúcar agregado, yogurt natural sin azúcar, cacao, aceite de oliva, aceite de coco, orégano, canela, vinagre de manzana. Manzana y pera cocida
• Verduras cocidas ( zanahoria, batata, auyama). Así como también, alcachofas, kale, repollo morado, espárragos, cebolla cruda (microdosis), ajo, mantequilla clarificada, plátano verde cocido, aguacate y frutos secos activados.
• Higado de res en microdosis.
Objetivos:
• Reducir bacterias proinflamatorias.
• Restaurar la integridad de la barrera mucosa inmunológica intestinal.
• Prevenir sobrecrecimiento de oportunistas y hongos.
• Restaurar la microbiotica simbiótica.
Probióticos recomendados por fase:
Indicaciones: tomar una capsula diaria en ayuna con bebidas fresca no calientes y lejos de antibióticos.
Fase 1: 8 semanas. De las cuales 2 semanas media dosis, luego continuar dosis completa.
Bifidobacterium breve, B. bifidum infantis, B. longum.
Lactobacillus plantarum, L. rhamnosus. 10 mil millones UFC/día. En polvo.
Fase 2: 12 semanas
Probióticos de almidón resistente. Pediátrico.1 sobre/día.
Fase3: 12 semanas
Akkermansia muciniphila. 1cápsula/semana.
Fase de mantenimiento: 6 semana de refuerzo
Saccharomyces boulardii. 5 mil UFC/DÍA. Evaluar tolerancia.
Se recomienda evaluar zonulina.
Evaluación de microbiota en 4 meses.
• pH: alcalina
• Color Marrón
• Consistencia: Blandas
• Restos de alimentos presentes.
- Parásitos: No se observaron formas parasitarias.
- Blastosporas (levaduras): No observadas.
- Pseudohifas: No observadas.
La diversidad bacteriana es un buen indicador de la salud intestinal. Una mayor diversidad suele estar asociada con una mejor salud digestiva y un mejor sistema inmunológico. Puede disminuir en respuesta a terapias con antibióticos, infecciones, la edad, las dietas desequilibradas o el tabaquismo.
El microbioma intestinal esta dividido en tres grupos bacterianos dominantes, asociados con diferentes perfiles metabólicos y funciones en el organismo. Enterotipo 1 Enterotipo 2 Enterotipo 3. El paciente es del grupo 1. Proteolítico.
La proporcion bacteriana en el tracto intestinal puede variar considerablemente de persona a persona. Este indicativo refleja el equilibrio cuantitativo de una microbiota benefica y una microbiota potencialmente patogena.
Firmicutes / Bacteroidetes
Reference Value: 1.5 - 2.5
Actinobacteria / Proteobacteria
Reference Value > 1.0
Prevotella / Bacteroides
Reference Value: 0.1 - 1.0
| Fila | RESULT ( ABSOLUTE, Lg (GE/g feces)*) | RELATIVE, VALUE % |
|---|---|---|
| Actinobacteria | 10,00 | 210,20 % |
| Firmicutes | 7,22 | 63,60 % |
| Bacteroidetes | 6,92 | 32,40 % |
| Fusobacteria | 0,00 | 0,00 % |
| Verrumicrobia | 5,30 | 0,80 % |
| Proteobacteria | 6,16 | 5,60 % |
| Otros | 0,00 | 0,00 % |
| NAME OF RESEARCH | RESULT ( ABSOLUTE, Lg (GE/g feces)*) | REFERENCE INTERVAL ( ABSOLUTE, Lg (GE/g feces)*) | RELATIVE, VALUE % | REFERENCE INTERVAL % |
|---|---|---|---|---|
| ACTINOBACTERIA*PACIENTE: 210,2%*V.R: 30-60% | ||||
| Bifidobacterium adolescentis | 4.2 | 5.5 - 7.5 | 12.5 | 1.0 - 5.0 |
| Bifidobacterium animalis subsp. lactis | - | 4.5 - 7.5 | - | 1.0 - 4.0 |
| Bifidobacterium breve | - | 4.5 - 6.5 | - | 1.0 -3.0 |
| Bifidobacterium bifidum | 4.9 | 4.0 - 6.5 | 62.6 | 1.0 - 3.0 |
| Bifidobacterium catenulatum ssp | - | 4.5 - 7.0 | - | 1.0 - 4.0 |
| Bifidobacterium spp | 4.6 ↘ | 8.0 - 10.0 | 0.2 ↘ | 2.0 - 10.0 |
| Bifidobacterium dentium | - | 3.5 - 5.5 | - | < 1 |
| Bifidobacterium longum subsp. infantis | - | 4.5 - 6.5 | - | 1.0 - 3.0 |
| Bifidobacterium longum subsp. longum | 4.5 | 5.5 - 7.5 | 24.9 | 2.0 - 6.0 |
| Coriobacteriia | - ↘ | < 0.5 | - | < 0.5 |
| "Metabolically active ""adult"" bifidobacteria **" | 4.2 ↘ | 5.0 - 7.6 | 12.5 ↘ | 85.0 - 95.0 |
| "Metabolically active ""infant"" bifidobacteria **" | 5.0 | 5.8 - 7.1 | 87.5 | 5.0 - 15.0 |
| Metabolically active bifidobacteria species, proportion | 10,0 | >10 | > 10 | >10 |
| FIRMICUTES*PACIENTE: 63,6%*V.R: 20-40% | ||||
| Clostridium difficile gr | 5.1 | 0.0 - 4.0 | 0.5 | < 1.0 |
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Dialister+Allisonella+Megasphaera+Veillonella | - ↘ | 5.7 - 7.5 | - | < 1.0 |
| Faecalibacterium prausnitzii | 5.8 | 6.5 - 9.0 | 2.4 | 3.0 - 10.0 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Erysipelotrichaceae | - | 3.7 - 8.5 | - | 0.0 - 6.0 |
| Lachnospiraceae | 6.9 ↘ | 7.5 - 10.0 | 30.6 | 10.0 - 30.0 |
| Peptoniphilaceae | - | 0.0 - 1.0 | - | < 0.1 |
| Lactococcus lactis | - | < 4.0 | - | < 0.5 |
| Streptococcus spp | - ↘ | 5.5 - 8.6 | - | < 1.0 |
| BACTEROIDETES*PACIENTE: 32,4%*V.R: 30-50% | ||||
| Prevotella spp | 6.6 | 6.5 - 8.5 | 15.3 | 5.0 - 15.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Parabacteroides spp | 5.4 ↘ | 3.7 - 6.5 | 1.0 | < 1.0 |
| Butyricimonas spp | - ↘ | 4.5 - 6.5 | - | < 0.5 |
| FUSOBACTERIA | ||||
| Fusobacteriaceae | - | 0.0 - 6.5 | - | 0.0 - 1.0 |
| VERRUMICROBIA | ||||
| Akkermansia muciniphila | 5.3 | 6.0 - 8.5 | 0.8 | 1.0 - 5.0 |
| NAME OF RESEARCH | RESULT ( ABSOLUTE, Lg (GE/g feces)*) | REFERENCE INTERVAL ( ABSOLUTE, Lg (GE/g feces)*) | RELATIVE, VALUE % | REFERENCE INTERVAL % |
|---|---|---|---|---|
| PROTEOBACTERIAS*PACIENTE: 5,6%*V.R: <1% | ||||
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| MICROBIOTA PROTECTORA*PACIENTE: 3,4%*V.R: 30-60% | ||||
| Bifidobacterium adolescentis | 4.2 | 5.5 - 7.5 | 12.5 | 1.0 - 5.0 |
| Akkermansia muciniphila | 5.3 | 6.0 - 8.5 | 0.8 | 1.0 - 5.0 |
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Bifidobacterium breve | - | 4.5 - 6.5 | - | 1.0 -3.0 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Bifidobacterium catenulatum ssp | - | 4.5 - 7.0 | - | 1.0 - 4.0 |
| Faecalibacterium prausnitzii | 5.8 | 6.5 - 9.0 | 2.4 | 3.0 - 10.0 |
| Bifidobacterium spp | 4.6 ↘ | 8.0 - 10.0 | 0.2 ↘ | 2.0 - 10.0 |
| Bifidobacterium dentium | - | 3.5 - 5.5 | - | < 1 |
| Lachnospiraceae | 6.9 ↘ | 7.5 - 10.0 | 30.6 | 10.0 - 30.0 |
| Bifidobacterium longum subsp. infantis | - | 4.5 - 6.5 | - | 1.0 - 3.0 |
| BACTERIAS INMUNOESTIMULANTES (BENEFICIOSAS)*PACIENTE: 3,4%*V.R: 40-70% | ||||
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Akkermansia muciniphila | 5.3 | 6.0 - 8.5 | 0.8 | 1.0 - 5.0 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Bifidobacterium spp | 4.6 ↘ | 8.0 - 10.0 | 0.2 ↘ | 2.0 - 10.0 |
| Faecalibacterium prausnitzii | 5.8 | 6.5 - 9.0 | 2.4 | 3.0 - 10.0 |
| B. PRODUCTORAS/FACILITADORA DE MUCINA*PACIENTE: 2,4%*V.R: 1-4% / 40-70% | ||||
| Akkermansia muciniphila | 5.3 | 6.0 - 8.5 | 0.8 | 1.0 - 5.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Parabacteroides spp | 5.4 ↘ | 3.7 - 6.5 | 1.0 | < 1.0 |
| Faecalibacterium prausnitzii | 5.8 | 6.5 - 9.0 | 2.4 | 3.0 - 10.0 |
| Lachnospiraceae | 6.9 ↘ | 7.5 - 10.0 | 30.6 | 10.0 - 30.0 |
| BACTERIAS FORMADORAS DE BUTIRATO*PACIENTE: 68,3%*V.R: 40-60% | ||||
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Butyricimonas spp | - ↘ | 4.5 - 6.5 | - | < 0.5 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Faecalibacterium prausnitzii | 5.8 | 6.5 - 9.0 | 2.4 | 3.0 - 10.0 |
| Lachnospiraceae | 6.9 ↘ | 7.5 - 10.0 | 30.6 | 10.0 - 30.0 |
| PATOGENOS OPORTUNISTAS*PACIENTE: 5,3% | ||||
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| Clostridium difficile gr | 5.1 | 0.0 - 4.0 | 0.5 | < 1.0 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Fusobacteriaceae | - | 0.0 - 6.5 | - | 0.0 - 1.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Erysipelotrichaceae | - | 3.7 - 8.5 | - | 0.0 - 6.0 |
| Peptoniphilaceae | - | 0.0 - 1.0 | - | < 0.1 |
| NAME OF RESEARCH | RESULT ( ABSOLUTE, Lg (GE/g feces)*) | REFERENCE INTERVAL ( ABSOLUTE, Lg (GE/g feces)*) | RELATIVE, VALUE % | REFERENCE INTERVAL % |
|---|---|---|---|---|
| M. PROINFLAMATORIA (POTENCIALMENTE PERJUDICIAL)*PACIENTE: 21,3%*V.R: <20% | ||||
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Staphylococcus aureus | - | 0.0 - 0.5 | - | 0.0 - 0.1 |
| M.PRODUCTORA DE H2S*PACIENTE: 0,7%*V.R: 0-1% | ||||
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Erysipelotrichaceae | - | 3.7 - 8.5 | - | 0.0 - 6.0 |
| M. PRODUCTORA DE HISTAMINA*PACIENTE: 0,4%*V.R: <1% | ||||
| Clostridium difficile gr | 5.1 | 0.0 - 4.0 | 0.5 | < 1.0 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Lactobacillaceae | - | 7.0 - 9.0 | - | 0.0 - 5.0 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Staphylococcus aureus | - | 0.0 - 0.5 | - | 0.0 - 0.1 |
| M. PRODUCTORA DE TMA Y TMAO*PACIENTE: 1,0%*V.R: <2% | ||||
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| M. PRODUCTORES DE AMONIACO*PACIENTE: 85,5%*V.R: <70% | ||||
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| NAME OF RESEARCH | RESULT ( ABSOLUTE, Lg (GE/g feces)*) | REFERENCE INTERVAL ( ABSOLUTE, Lg (GE/g feces)*) | RELATIVE, VALUE % | REFERENCE INTERVAL % |
|---|---|---|---|---|
| M. PRODUCTORA DE FENOLES*PACIENTE: 85,5%*V.R: <60% | ||||
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Fusobacteriaceae | - | 0.0 - 6.5 | - | 0.0 - 1.0 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Staphylococcus spp | - | 0.0 - 5.5 | - | 0.0 - 0.3 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Peptoniphilaceae | - | 0.0 - 1.0 | - | < 0.1 |
| M.PRODUCTORES DE ACIDOS BILIARES SECUNDARIOS*PACIENTE: 85,5%*V.R: <75% | ||||
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Clostridium leptum gr | 6.9 | 7.0 - 9.0 | 30.6 | 10 - 25.0 |
| Lachnospiraceae | 6.9 ↘ | 7.5 - 10.0 | 30.6 | 10.0 - 30.0 |
| M.PRODUCTORA DE SULFATO DE INDOXILO*PACIENTE: 85,7%*V.R: <60% | ||||
| Alistipes spp | 6.6 | 7.0 - 9.0 | 15.3 | 2.8 - 8.0 |
| Bacteroides spp | 5.3 ↘ | 7.5 - 9.5 | 0.8 | 5.0 - 25.0 |
| Clostridium perfringens gr | - | 0.0 - 5.0 | - | 0.0 - 0.5 |
| Desulfovibrio spp | 5.3 | 4.5 - 6.5 | 0.8 | < 1.0 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| E.coli | 5.9 | 4.0 - 6.5 | 3.1 | < 1.0 |
| Enterobacterales | 5.6 | 4.0 - 6.5 | 1.5 | < 1.5 |
| Peptoniphilaceae | - | 0.0 - 1.0 | - | < 0.1 |
| MARCADORES DE PATOGENICIDAD Y RESISTENCIA*PACIENTE: NO HAY SOBRECRECIMIENTO NI RESISTENCIA | ||||
| Clostridioides difficile | - | 0.0 - 4.4 | - | 0.0 - 0.3 |
| Pseudomonas spp | 4.7 | 0.0 - 5.0 | 0.2 ↗ | < 0.3 |
| mecA | - | 0.0 - 0.0 | - | ND |
| tcdA tcdB | - | 0.0 - 0.0 | - | ND |
| srr2 | - | 0.0 - 0.1 | - | |
| Enterococcus spp | - | < 4.5 | - | 0.0 - 0.5 |
| Streptococcus agalactiae | - | 0.0 - 0.1 | - | 0.0 - 0.1 |
| Staphylococcus aureus | - | 0.0 - 0.5 | - | 0.0 - 0.1 |
| HONGOS Y LEVADURAS | ||||
| C.albicans | - | 0.0 - 3.5 | - | < 0.1 |
| Candida spp | 5.8 | 0.0 - 4.0 | - | < 0.5 |
| ARQUEAS | ||||
| Methanobrevibacter spp | - | 4.5 - 7.5 | - | < 1.0 |